STOCK TITAN

Corcept officer buys 328 shares, 91 withheld for tax

Corcept Therapeutics’ chief business officer reported small equity grants, a tax withholding share disposition, and indirect trust and custodial holdings.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) reported insider equity activity by Chief Business Officer Gary Charles Robb. On September 1, 2026, he acquired 164 shares of common stock through a purchase plan and a further 164 shares underlying restricted stock awards, which vest after one year if specified conditions are met. On September 2, 2026, 91 shares were withheld by the company to satisfy tax withholding obligations upon vesting of restricted stock units. He also reports indirect ownership of 39,716 shares held in a revocable trust, plus additional shares in custodial accounts for his children.

Positive

  • None.

Negative

  • None.
Insider Robb Gary Charles
Role Chief Business Officer
Type Security Shares Price Value
Tax Withholding Common Stock F5, F6, F7 91 $113.38 $10K
Grant/Award Common Stock F1, F2, F3 164 $113.38 $19K
Grant/Award Common Stock F4, F3 164 $0.00 $0.00
holding Common Stock F8 -- -- --
holding Common Stock F9 -- -- --
holding Common Stock F10 -- -- --
Holdings After Transaction: Common Stock — 13,663 shares (Direct); Common Stock — 39,716 shares (Indirect, Gary Charles Robb TTE Robb Revocable Trust); Common Stock — 31,142 shares (Indirect, Custodial Account for Child)
Footnotes (10)
  1. F1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
  2. F2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  3. F3. Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  4. F4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  5. F5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  6. F6. The closing price on September 1, 2026 was used to calculate the withholding obligation.
  7. F7. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  8. F8. These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
  9. F9. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
  10. F10. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
Purchase plan shares acquired 164 shares Common stock purchased on September 1, 2026 under a purchase plan
Additional restricted shares granted 164 shares Common stock underlying unvested restricted stock awards on September 1, 2026
Shares withheld for tax 91 shares Common stock withheld September 2, 2026 to satisfy tax withholding obligations
Reference closing price $113.38 per share Closing price on September 1, 2026 used for purchase plan and tax calculation
Indirect trust holdings 39,716 shares Common stock held by Gary Charles Robb TTE Robb Revocable Trust
Unvested restricted stock from prior grants 1,499 shares Total unvested restricted stock from 2025–2026 grants included in holdings
restricted stock awards financial
"Includes 251 shares underlying unvested restricted stock awards granted"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
restricted stock units financial
"in connection with the issuance of shares upon the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Uniform Transfers to Minors Act regulatory
"custodial account under the Uniform Transfers to Minors Act for which"
Incentive Award Plan financial
"established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan"
An incentive award plan is a formal program that rewards employees, executives, or directors with cash, stock, options, or other pay when the company meets set goals or performance targets. Like a sales commission or a loyalty program that pays out when you hit milestones, it’s designed to align staff behavior with company objectives; investors care because it affects a company’s costs, share count (dilution), leadership incentives, and long-term value creation.

FAQ

What insider transactions did CORT’s Chief Business Officer report on this Form 4?

The Chief Business Officer reported two acquisitions of 164 shares each of Corcept Therapeutics common stock on September 1, 2026, related to a purchase plan and restricted stock awards, and a disposition of 91 shares on September 2, 2026, withheld for tax obligations.

How many Corcept Therapeutics (CORT) shares were acquired through the purchase plan?

On September 1, 2026, the reporting person acquired 164 Purchase Plan Shares of Corcept Therapeutics common stock pursuant to a purchase plan established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan, with the price based on the closing price that day.

What are the vesting terms of the new restricted stock awards at CORT?

The filing states that 100% of the shares underlying the relevant restricted stock awards vest on the one-year anniversary of the grant date, provided the reporting person satisfies certain requirements, including in some cases remaining the beneficial owner of the purchase plan shares.

Why were 91 CORT shares disposed of on September 2, 2026?

The 91 shares of Corcept Therapeutics common stock reported as disposed of on September 2, 2026 were withheld by the company to satisfy tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

What indirect holdings of Corcept Therapeutics (CORT) stock does the insider report?

The insider reports 39,716 shares of Corcept Therapeutics common stock held indirectly through the Gary Charles Robb TTE Robb Revocable Trust, where he is trustee, plus additional shares held for his children in custodial accounts under the Uniform Transfers to Minors Act.

Were the reported CORT transactions made under a Rule 10b5-1 trading plan?

The form’s Rule 10b5-1 checkbox is not checked, and there is no footnote stating that the reported transactions were made under a Rule 10b5-1 trading plan, although some shares were acquired under a purchase plan established under the 2024 Incentive Award Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Robb Gary Charles

(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026A164(1)A$113.38(2)13,590(3)D
Common Stock09/01/2026A164(4)A$013,754(3)D
Common Stock09/02/2026F(5)91D$113.38(6)13,663(7)D
Common Stock39,716IGary Charles Robb TTE Robb Revocable Trust(8)
Common Stock15,571ICustodial Account for Child(9)
Common Stock15,571ICustodial Account for Child(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
3. Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
6. The closing price on September 1, 2026 was used to calculate the withholding obligation.
7. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
8. These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
9. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
10. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading